Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis.[7] It is a tyrosine kinase 2 (TYK2) inhibitor and it is taken by mouth.[7] It was developed by Bristol Myers Squibb.[10]
Deucravacitinib was approved for medical use in the United States in September 2022,[7][11][12] and in Australia in December 2022.[1] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[13][14]
^ abc"Sotyktu". Therapeutic Goods Administration (TGA). 14 December 2022. Archived from the original on 9 June 2023. Retrieved 15 April 2023.
^"Sotyktu (Bristol-Myers Squibb Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Archived from the original on 27 March 2023. Retrieved 9 April 2023.
^"Details for: Sotyktu". Health Canada. 14 February 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
^"Notice: Multiple Additions to the Prescription Drug List (PDL) [2023-03-08]". Health Canada. 8 March 2023. Archived from the original on 22 March 2023. Retrieved 21 March 2023.
^"Summary Basis of Decision - Sotyktu". Health Canada. 10 March 2023. Archived from the original on 25 April 2023. Retrieved 24 April 2023.
^"Sotyktu Summary of Product Characteristics (SmPC)". (emc). 13 July 2023. Archived from the original on 20 December 2023. Retrieved 20 December 2023.
^ abcd"Sotyktu- deucravacitinib tablet, film coated". DailyMed. 9 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
^"Sotyktu EPAR". European Medicines Agency (EMA). 24 March 2023. Archived from the original on 19 February 2024. Retrieved 3 March 2024.
^"Sotyktu". Union Register of medicinal products. 27 March 2023. Archived from the original on 31 March 2023. Retrieved 30 March 2023.
^"U.S. Food and Drug Administration Approves Sotyktu (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis" (Press release). Bristol Myers Squibb. 10 September 2022. Archived from the original on 10 September 2022. Retrieved 10 September 2022 – via Business Wire.
^"Drug Approval Package: Sotyktu". U.S. Food and Drug Administration (FDA). 14 October 2022. Archived from the original on 5 January 2023. Retrieved 4 January 2023.
^Truong TM, Pathak GN, Singal A, Taranto V, Rao BK (June 2023). "Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis". The Annals of Pharmacotherapy: 10600280231153863. doi:10.1177/10600280231153863. PMID 37341177. S2CID 259211735.
^"Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Archived from the original on 21 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
^New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.
Deucravacitinib, sold under the brand name Sotyktu, is medication used for the treatment of moderate-to-severe plaque psoriasis. It is a tyrosine kinase...
myelofibrosis, myeloproliferative neoplasms and myelodysplastic syndrome. Deucravacitinib is currently in clinical trials for psoriatic arthritis, inflammatory...
of tetrabenazine, which had been approved earlier for the same use. Deucravacitinib is a deuterated JAK inhibitor (specifically, TYK2 inhibitor) approved...
approved for the use in active psoriatic arthritis. The TYK2 inhibitor deucravacitinib (Sotyktu), which has been approved for plaque psoriasis, is currently...
Global Information
This article incorporates text from this source, which is in the public domain.
